Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Granger

Showing results (611-620 of 1,253) with videos related to

Pageof 126
Sort By:
Critical Care Nurse|January 31, 2025
A Rapid-Cycle Intervention to Enhance Patient and Family Satisfaction in the Intensive Care UnitHeather Pena, Jason Stokes, Lauren Zulueta, et al.
American Heart Journal|January 3, 2020
Gastrointestinal bleeding in patients with atrial fibrillation treated with Apixaban or warfarin: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trialDavid A Garcia, Deborah A Fisher, Hillary Mulder, et al.
European Journal of Preventive Cardiology|November 9, 2019
Effects of apixaban compared with warfarin as gain in event-free time - a novel assessment of the results of the ARISTOTLE trialErik Berglund, Lars Wallentin, Jonas Oldgren, et al.
American Heart Journal|May 3, 2005
Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary interventionPaul W Armstrong, Peter X Adams, Hussein R Al-Khalidi, et al.
American Heart Journal|January 31, 2006
Cardiac tamponade in the fibrinolytic era: analysis of >100,000 patients with ST-segment elevation myocardial infarctionManesh R Patel, Trip J Meine, Lauren Lindblad, et al.
European Journal of Heart Failure|February 5, 2008
Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trialR A P Weir, John J V McMurray, Margareta Puu, et al.
JACC. Cardiovascular Interventions|March 20, 2010
Prior coronary artery bypass graft patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary interventionRobert C Welsh, Christopher B Granger, Cynthia M Westerhout, et al.
American Heart Journal|January 8, 1999
Death and nonfatal reinfarction within the first 24 hours after presentation with an acute coronary syndrome: experience from GUSTO-IIb. Global Utilization of Strategies for Total OcclusionN S Kleiman, C B Granger, H D White, et al.
Circulation|December 7, 2005
Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patientsScott D Solomon, Nagesh Anavekar, Hicham Skali, et al.
European Heart Journal|October 29, 2000
Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb study. GUSTO IIb InvestigatorsD K McGuire, H Emanuelsson, C B Granger, et al.
Pageof 126

Showing results (611-620 of 1,253) with videos related to

Sort By:
Pageof 126
Critical Care Nurse|January 31, 2025
A Rapid-Cycle Intervention to Enhance Patient and Family Satisfaction in the Intensive Care UnitHeather Pena, Jason Stokes, Lauren Zulueta, et al.
American Heart Journal|January 3, 2020
Gastrointestinal bleeding in patients with atrial fibrillation treated with Apixaban or warfarin: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trialDavid A Garcia, Deborah A Fisher, Hillary Mulder, et al.
European Journal of Preventive Cardiology|November 9, 2019
Effects of apixaban compared with warfarin as gain in event-free time - a novel assessment of the results of the ARISTOTLE trialErik Berglund, Lars Wallentin, Jonas Oldgren, et al.
American Heart Journal|May 3, 2005
Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary interventionPaul W Armstrong, Peter X Adams, Hussein R Al-Khalidi, et al.
American Heart Journal|January 31, 2006
Cardiac tamponade in the fibrinolytic era: analysis of >100,000 patients with ST-segment elevation myocardial infarctionManesh R Patel, Trip J Meine, Lauren Lindblad, et al.
European Journal of Heart Failure|February 5, 2008
Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trialR A P Weir, John J V McMurray, Margareta Puu, et al.
JACC. Cardiovascular Interventions|March 20, 2010
Prior coronary artery bypass graft patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary interventionRobert C Welsh, Christopher B Granger, Cynthia M Westerhout, et al.
American Heart Journal|January 8, 1999
Death and nonfatal reinfarction within the first 24 hours after presentation with an acute coronary syndrome: experience from GUSTO-IIb. Global Utilization of Strategies for Total OcclusionN S Kleiman, C B Granger, H D White, et al.
Circulation|December 7, 2005
Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patientsScott D Solomon, Nagesh Anavekar, Hicham Skali, et al.
European Heart Journal|October 29, 2000
Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb study. GUSTO IIb InvestigatorsD K McGuire, H Emanuelsson, C B Granger, et al.
Pageof 126